Jupiter Endovascular

Executive Summary

Jupiter Endovascular is developing a transformative catheter technology called Transforming Fixation (TFX) that dynamically switches between flexible and rigid states, aiming to improve stability and access in complex vascular procedures. The company's initial clinical target is pulmonary embolism, a life-threatening condition with significant unmet need. By enabling better catheter control, TFX has the potential to reduce procedure times and improve patient outcomes. The device addresses a key limitation in current endovascular tools: maintaining precise positioning during interventions. While still in early-stage development, the technology has garnered interest for its novel approach. The company is privately held and based in Miami, Florida. The global pulmonary embolism device market is sizable, presenting a large opportunity if the TFX technology can demonstrate clinical superiority. However, as a preclinical company with no regulatory approvals to date, Jupiter Endovascular faces typical risks including capital requirements, clinical validation, and competitive pressures.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) submission for TFX catheter in pulmonary embolism55% success
• Q2 2026Presentation of first-in-human clinical data at major vascular conference65% success
• TBDStrategic partnership or funding round for commercial development60% success